Stoke Therapeutics, Inc. Investment Income, Interest
Stoke Therapeutics, Inc. (STOK) reported Investment Income, Interest of $3.52 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-03
- Stoke Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $3.52M, a 7.17% decline year-over-year.
- Stoke Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $3.42M, a 18.34% increase year-over-year.
- Stoke Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $3.62M, a 21.86% increase year-over-year.
- Stoke Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $3.47M, a 2.23% decline year-over-year.
- Stoke Therapeutics, Inc. investment income, interest for fiscal 2025 was $13.77M, a 8.69% increase from fiscal 2024.
- Stoke Therapeutics, Inc. investment income, interest for fiscal 2024 was $12.66M, a 27.19% increase from fiscal 2023.
- Stoke Therapeutics, Inc. investment income, interest for fiscal 2023 was $9.96M.
- Stoke Therapeutics, Inc. investment income, interest for fiscal 2020 was $744.00K, a 77.80% decline from fiscal 2019.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.52M 10-Q · filed 2026-08-03 | $6.94M 10-Q · filed 2026-08-03 | $10.56M derived: sum of 3 quarters · filed 2026-08-03 | $14.02M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $3.42M 10-Q · filed 2026-05-07 | $7.04M derived: sum of 2 quarters · filed 2026-05-07 | $10.50M derived: sum of 3 quarters · filed 2026-05-07 | $14.30M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $3.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $7.08M derived: sum of 2 quarters · filed 2026-03-16 | $10.88M derived: sum of 3 quarters · filed 2026-08-03 | $13.77M 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.47M 10-Q · filed 2025-11-04 | $7.26M derived: sum of 2 quarters · filed 2026-08-03 | $10.15M 10-Q · filed 2025-11-04 | $13.12M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $3.79M 10-Q · filed 2026-08-03 | $6.68M 10-Q · filed 2026-08-03 | $9.65M derived: sum of 3 quarters · filed 2026-08-03 | $13.20M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $2.89M 10-Q · filed 2026-05-07 | $5.86M derived: sum of 2 quarters · filed 2026-05-07 | $9.40M derived: sum of 3 quarters · filed 2026-05-07 | $13.10M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.97M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $6.51M derived: sum of 2 quarters · filed 2026-03-16 | $10.21M derived: sum of 3 quarters · filed 2026-03-16 | $12.66M 10-K · filed 2026-03-16 |
| 2024-09-30 | $3.54M 10-Q · filed 2025-11-04 | $7.25M derived: sum of 2 quarters · filed 2025-11-04 | $9.70M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $3.70M 10-Q · filed 2025-08-12 | $6.15M 10-Q · filed 2025-08-12 | ||
| 2024-03-31 | $2.45M 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $9.96M 10-K · filed 2025-03-18 | |||
| 2021-03-31 | $18.00K 10-Q · filed 2021-05-10 | $28.00K derived: sum of 2 quarters · filed 2021-05-10 | $39.00K derived: sum of 3 quarters · filed 2021-05-10 | $89.00K derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $21.00K derived: sum of 2 quarters · filed 2021-03-09 | $71.00K derived: sum of 3 quarters · filed 2021-03-09 | $744.00K 10-K · filed 2021-03-09 |
| 2020-09-30 | $11.00K 10-Q · filed 2020-11-12 | $61.00K derived: sum of 2 quarters · filed 2020-11-12 | $734.00K 10-Q · filed 2020-11-12 | $1.64M derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-06-30 | $50.00K 10-Q · filed 2020-08-10 | $723.00K 10-Q · filed 2020-08-10 | $1.63M derived: sum of 3 quarters · filed 2021-05-10 | $2.86M derived: sum of 4 quarters · filed 2021-05-10 |
| 2020-03-31 | $674.00K 10-Q · filed 2021-05-10 | $1.58M derived: sum of 2 quarters · filed 2021-05-10 | $2.81M derived: sum of 3 quarters · filed 2021-05-10 | $3.44M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $904.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $2.14M derived: sum of 2 quarters · filed 2021-03-09 | $2.77M derived: sum of 3 quarters · filed 2021-03-09 | $3.35M 10-K · filed 2021-03-09 |
| 2019-09-30 | $1.24M 10-Q · filed 2020-11-12 | $1.86M derived: sum of 2 quarters · filed 2020-11-12 | $2.45M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $629.00K 10-Q · filed 2020-08-10 | $1.21M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $580.00K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | $270.00K 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |